Global Med Technologies(R) Receives Key Patent Approval
2007年7月11日 - 10:00PM
PRニュース・ワイアー (英語)
Remote Crossmatch to Facilitate Just-In-Time Inventory Management
DENVER, July 11 /PRNewswire-FirstCall/ -- Global Med
Technologies(R), Inc. (OTC:GLOB) (BULLETIN BOARD: GLOB) , an
international e-Health, medical information technology company,
today announced that the United States Patent and Trademark Office
will be issuing a patent for SafeTrace Tx(R), its proprietary
transfusion software, which is located at more than 337 sites in
the United States and abroad. Issuance of a patent for SafeTrace Tx
is significant, demonstrating that software developed by Global
Med's Wyndgate Technologies(R) division contains distinctive
features which separate it from other blood management software
programs. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)
SafeTrace Tx is innovative blood management software which helps to
raise the standard of care for patients, through improved safety,
reduced waste and increased efficiency. The ability of SafeTrace Tx
to handle remote crossmatching of blood is among the features
covered by the patent announcement. The software enables laboratory
staff to more effectively manage orders and to provide just-in-time
inventory management of blood products while streamlining
laboratory workload and expense. Transfusion services have reported
cost reductions by using SafeTrace Tx to optimize operations and
increase efficiency. Mick Ruxin, M.D., Chairman and CEO, stated,
"The Institute for Transfusion Medicine in Pittsburgh, along with
many other Wyndgate customers, has been using remote crossmatch for
years to facilitate just-in-time inventory management. This feature
helps them to streamline their operations and increase
efficiencies. By using the newly patent-approved remote crossmatch
function, SafeTrace Tx helps to prevent excess blood waste by
selecting the best inventory for transfusion from any of their
networked facilities." Thomas F. Marcinek, President and Chief
Operating Officer for Wyndgate Technologies, further stated, "As
the inventors of patented software, Wyndgate is now in a stronger
position in the blood management system marketplace. We are looking
forward to adding to our growing list of customers in the United
States and abroad who have selected our products to manage their
transfusion services." Mr. Marcinek added, "Like the facilities we
serve, we are committed to high quality patient care and safety
through the effective application of technology." About Global Med
Technologies, Inc. Global Med Technologies, Inc. is an
international e-Health medical information technology company
providing information management software products and services to
the healthcare industry. Its Wyndgate Technologies division is a
leading supplier of information management systems to U.S. and
international blood centers and hospital transfusion centers. Each
year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood
supply. Wyndgate's products are being used in Canada and
sub-Saharan Africa, and are being implemented in the Caribbean.
Together, the Donor Doc(TM) interactive donor health history
questionnaire, SafeTrace(R) donor management system and the
SafeTrace Tx(R) advanced transfusion management system provide
Vein-to-Vein(R) tracking from donor collection to patient
transfusion. For more information about Global Med's products and
services, please call 800-WYNDGATE or visit
http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release.
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D., of Global Med Technologies,
Inc., +1-303-238-2000; or investors, Paul Holm of H.L. Lanzet,
+1-212-888-4570, , for Global Med Technologies(R), Inc. Web site:
http://www.globalmedtech.com/ http://www.peoplemed.com/
http://www.wyndgate.com/
Copyright